Malvern Instruments CTO will Discuss New Technology for Characterizing Protein Formulations at International BioAnalytical Congress
Dr E. Neil Lewis, Chief Technology Officer at Malvern Instruments and Head of the company’s Bioscience Development Initiative, will speak at the International BioAnalytical Congress taking place in Berlin (Germany) on 11 and 12 September 2013.
The theme of the conference is the future of bioanalytical development and Dr Lewis will discuss ‘Advances in the integrated measurements of higher order proteins’, focusing especially on new technology that combines dynamic light scattering with Raman spectroscopy. He will examine this as a means of providing structural, thermodynamic and kinetic insights into mechanisms of protein aggregation and the factors that influence protein stability. Malvern is pleased also to be a sponsor and exhibitor at the Congress.
Determining the ease with which a protein therapeutic can be developed, formulated and manufactured requires non-invasive, non-destructive measurement of numerous physicochemical properties, including viscosity, protein structure and hydrodynamic size. Malvern offers a growing portfolio of analytical technologies focused on the needs of biopharmaceutical developers, including:
The new Viscosizer 200 which automates low volume viscosity measurement and size analysis. It is ideally placed to serve those working within biopharmaceutical preformulation and formulation development who need rapid viscosity information on a large number of low volume samples, in order to assess candidate developability.
Archimedes, which uses the technique of resonant mass measurement to detect and count particles in the size range 50 nm–5 µm. It is especially useful for characterising protein aggregates in formulation or buffer.
The Zetasizer Nano ZSP for the measurement of size, electrophoretic mobility of proteins, zeta potential of nanoparticles and surfaces, and optionally the microrheology of protein and polymer solutions. Protein mobility is one property that has been identified as a promising indicator of formulation stability, viscosity, and behavior.
Viscotek SEC-MALS 20 extends Malvern’s family of light scattering detectors for measuring the absolute molecular weight of proteins, macromolecules and polymers. Static light scattering is widely used within gel permeation/size exclusion chromatography (GPC/SEC) for the determination of the absolute molecular weight of protein, polymer and macromolecular species without the need for external, potentially inaccurate calibrations.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...